PLACENTEX ¿ Polydeoxyribonucleotide 5.625 mg/3 ml ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 51 | 全身性強皮症 | 1 |
51. 全身性強皮症
臨床試験数 : 523 / 薬物数 : 608 - (DrugBank : 156) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 215
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2015-005100-28-IT (EUCTR) | 18/07/2016 | 17/01/2022 | A clinical trial to evaluate the efficacy and safety of PLACENTEX ¿ administered intra-muscular in patients with cutaneous lesions in scleroderma diseases. | A phase IV, single-arm, open-label clinical trial to evaluate the efficacy and safety of PLACENTEX ¿ Polydeoxyribonucleotide i.m. in patients with fibrotic and atrophic cutaneous lesions in scleroderma diseases. - A clinical trial to evaluate the efficacy and safety of PLACENTEX ¿ administered intra-muscular in p | Fibrotic and atrophic cutaneous lesions in localized scleroderma diseases. MedDRA version: 20.0;Level: HLT;Classification code 10039711;Term: Scleroderma and associated disorders;System Organ Class: 100000004870;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Trade Name: PLACENTEX ¿5.625 mg/3 ml soluzione iniettabile¿ Product Name: PLACENTEX ¿ Polydeoxyribonucleotide 5.625 mg/3 ml INN or Proposed INN: POLYDEOXYRIBONUCLEOTIDES Other descriptive name: PLACENTEX ® Polydeoxyribonucleotide | MASTELLI SRL | NULL | Not Recruiting | Female: yes Male: yes | 45 | Phase 4 | Italy |